Profound Medical Corp.
Profound Medical Corp. (PROF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
prof · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Profound Medical Corp. (PROF) measures how much investors pay for each dollar of the company's trailing earnings. PROF's current PE ratio of N/A is calculated by dividing its stock price of $6.57 by its TTM earnings per share of -$1.07.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2012 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Profound Medical Corp.You PROF | $199M | N/A | — | -$1.07 |
 Armata Pharmaceuticals, Inc. ARMP | $278M | N/A | — | -$4.80 |
 Anteris Technologies Global Corp. AVR | $344M | N/A | — | -$3.99 |
 Perspective Therapeutics, Inc. CATX | $226M | N/A | — | -$1.40 |
 LENSAR, Inc. LNSR | $68M | N/A | — | -$2.87 |
 MaxCyte, Inc. MXCT | $123M | N/A | — | -$0.42 |
 Nano-X Imaging Ltd. NNOX | $127M | N/A | — | -$1.16 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.43 | — | |
2024-12-31 FY2024 | — | $-1.07 | — | |
2023-12-31 FY2023 | — | $-1.35 | — | |
2022-12-31 FY2022 | — | $-1.38 | — | |
2021-12-31 FY2021 | — | $-1.50 | — | |
2020-12-31 FY2020 | — | $-1.25 | — | |
2019-12-31 FY2019 | — | $-1.37 | — | |
2018-12-31 FY2018 | — | $-1.52 | — | |
2017-12-31 FY2017 | — | $-2.44 | — | |
2016-12-31 FY2016 | — | $-2.93 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Profound Medical Corp. (PROF) measures how much investors pay for each dollar of the company's trailing earnings. PROF's current PE ratio of N/A is calculated by dividing its stock price of $6.57 by its TTM earnings per share of -$1.07.
Frequently asked questions
PROF pe ratio · 6 questionsPROF's current PE ratio is N/A as of 2026-06-08, based on a stock price of $6.57 and TTM EPS of -$1.07. Data sourced from Financial Modeling Prep via PROF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Profound Medical Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08